{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-065928","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.264439+00:00","generated_at":"2026-06-04T22:46:20.743932+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lexicon files certificate for Series A Convertible Preferred Stock; conversion requires charter amendment","bullets":["Each Preferred share converts into 50 common shares upon stockholder approval to increase authorized shares to 450M.","Conversion conditions include approval at 2024 annual meeting, board adoption, and Delaware filing of new charter.","Preferred stockholders vote on as-converted basis on all matters; no separate class vote.","Issuance is part of previously announced private placement; par value $0.01 per share.","Authorized common shares to increase from 300M to 450M under proposed Sixth Amended and Restated Charter."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-065928","json":"https://secwatch.observer/filing/0001193125-24-065928.json","markdown":"https://secwatch.observer/filing/0001193125-24-065928.md","text":"https://secwatch.observer/filing/0001193125-24-065928.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000119312524065928/0001193125-24-065928-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000119312524065928/d783185d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:46:20.743932+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"033c74dbe29b4e91d9323d62bd039e67a697d562","claim":"LEXICON PHARMACEUTICALS, INC.: Filing of Certificate of Designations for Series A Convertible Preferred Stock and planned increase in authorized common shares from 300,000,000 to 450,000,000 upon stockholder approval and adoption of New Charter (effective 2024-03-12).","evidence_excerpt":"On March 12, 2024, in connection with the previously announced private placement by Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “ Company ”), of preferred stock to be designated as Series A Convertible Preferred Stock, par value $0.01 per share (the “ Preferred Stock ”), the Company filed with the Secretary of State of the State of Delaware to be effective upon filing the Certificate of Designations of Series A Convertible Preferred Stock of the Company (the “ Certificate of Designations ”), in the form approved and adopted by the board of directors of the Company, which sets forth the terms of the Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000119312524065928/0001193125-24-065928-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-03-12"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}